Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Amortization of Deferred Charges (2016 - 2023)

Historic Amortization of Deferred Charges for Fate Therapeutics (FATE) over the last 12 years, with Q1 2023 value amounting to $7.2 million.

  • Fate Therapeutics' Amortization of Deferred Charges rose 55776.97% to $7.2 million in Q1 2023 from the same period last year, while for Dec 2023 it was $7.2 million, marking a year-over-year increase of 16890.88%. This contributed to the annual value of $7.2 million for FY2023, which is 16890.88% up from last year.
  • Latest data reveals that Fate Therapeutics reported Amortization of Deferred Charges of $7.2 million as of Q1 2023, which was up 55776.97% from $1.1 million recorded in Q4 2022.
  • In the past 5 years, Fate Therapeutics' Amortization of Deferred Charges registered a high of $7.2 million during Q1 2023, and its lowest value of -$331000.0 during Q2 2022.
  • Moreover, its 5-year median value for Amortization of Deferred Charges was $623000.0 (2021), whereas its average is $1.0 million.
  • Its Amortization of Deferred Charges has fluctuated over the past 5 years, first surged by 88930.48% in 2020, then crashed by 13381.0% in 2022.
  • Quarter analysis of 5 years shows Fate Therapeutics' Amortization of Deferred Charges stood at $187000.0 in 2019, then surged by 889.3% to $1.8 million in 2020, then plummeted by 30.43% to $1.3 million in 2021, then dropped by 12.2% to $1.1 million in 2022, then soared by 536.81% to $7.2 million in 2023.
  • Its Amortization of Deferred Charges was $7.2 million in Q1 2023, compared to $1.1 million in Q4 2022 and $783000.0 in Q3 2022.